Tarsus Pharmaceuticals, Inc. TARS
69.07 USD -3.57 (-4.91%)
At closeNov 4, 2026, 4:00 PM EST
69.07 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
65.34 Day range 74.63
53.89 52-week range 91.53
- YTD
- -15.64%
- 1 year
- -3.40%
Financial health
Altman Z-Score
-0.92 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
D+1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -51.5×
FY 2018 5y median -18.0× FY 2025
P/S 7.6×
FY 2018 5y median 11.4× FY 2025
P/B 10.0×
FY 2018 5y median 3.0× FY 2025
P/FCF -153×
FY 2018 5y median -7.3× FY 2025
EV/EBITDA -62.1×
FY 2018 5y median -19.3× FY 2025
EV/Sales 7.4×
FY 2018 5y median 11.3× FY 2025
FCF Yield -0.7%
FY 2018 5y median -4.1% FY 2025
Profitability
Gross Margin 93.2%
FY 2018 5y median 93.2% FY 2025
Operating Margin -15.7%
FY 2018 5y median -65.9% FY 2025
Net Margin -14.7%
FY 2018 5y median -63.2% FY 2025
ROE -19.3%
FY 2018 5y median -32.2% FY 2025
ROIC -16.6%
FY 2018 5y median -29.4% FY 2025
ROA -11.8%
FY 2018 5y median -27.2% FY 2025
Growth (YoY)
Revenue 146.7%
FY 2018 FY 2025
Operating Income 41.1%
FY 2018 FY 2025
EPS (diluted) 48.2%
FY 2018 FY 2025
Free Cash Flow 73.6%
FY 2018 FY 2025
Financial Health
Current Ratio 3.9×
FY 2018 5y median 6.9× FY 2025
Quick Ratio 3.8×
FY 2018 5y median 6.9× FY 2025
Debt / Equity 0.3×
FY 2018 5y median 0.2× FY 2025
Net Debt / EBITDA 1.7×
FY 2018 5y median 1.5× FY 2025
Interest Coverage -7.9×
FY 2018 5y median -16.2× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
